Bronchoscopic lung volume reduction in COPD lessons in implementing clinically based precision medicine

JAMA - Journal of the American Medical Association

Volumn 315, Issue 2, 2016, Pages 139-141

  Sciurba, Frank C ^a   Chandra, Divay ^a   Bon, Jessica ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; OXYGEN;

BRONCHOSCOPIC LUNG VOLUME REDUCTION; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EMPHYSEMA; ENDOBRONCHIAL COIL; ENDOBRONCHIAL VALVE; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG RESECTION; MINIMALLY INVASIVE SURGERY; PATIENT SELECTION; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME; RESPIRATORY THERAPEUTIC DEVICE; REVIEW; SAMPLE SIZE; TREATMENT OUTCOME; FEMALE; MALE;

BRONCHOSCOPY; EMPHYSEMA; FEMALE; HUMANS; MALE; PNEUMONECTOMY;

EID: 84954468181     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.17714     Document Type: Review

References (17)

1. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
2. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med. 2001; 345(15):1075-1083.
3. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059-2073.
4. Decker MR, Leverson GE, Jaoude WA, Maloney JD. Lung volume reduction surgery since the National Emphysema Treatment Trial: study of Society of Thoracic Surgeons Database. J Thorac Cardiovasc Surg. 2014;148(6):2651-2658.
5. Sciurba FC, Ernst A, Herth FJ, et al; VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363(13):1233-1244.
6. Klooster K, Ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med. 2015; 373(24):2325-2335.
7. Deslée G, Mal H, Dutau H, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical trial. JAMA. doi: 10.1001/jama.2015.17821.
8. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
9. Coxson HO, Nasute Fauerbach PV, Storness-Bliss C, et al. Computed tomography assessment of lung volume changes after bronchial valve treatment. Eur Respir J. 2008;32(6):1443-1450
10. Hartman JE, Klooster K, Gortzak K, ten Hacken NH, Slebos DJ. Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology. 2015;20(2):319-326.
11. Burrowes KS, Doel T, Brightling C. Computational modeling of the obstructive lung diseases asthma and COPD. J Transl Med. 2014;12 (suppl 2):S5.
12. Galbán CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012;18(11):1711-1715.
13. Hanmer J, Feeny D, Fischhoff B, et al. The PROMIS of QALYs. Health Qual Life Outcomes. 2015;13:122.
14. Normand C. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs. J Pain Symptom Manage. 2009;38(1):27-31.
15. Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(18):1-106.
16. Loveman E, Copley VR, Colquitt JL, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014;15:63.
17. Mapel DW, Roberts MH. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics. 2012;30(10):869-885.